|
|
| |
|
NeuroResearch Clinics relies exclusively
on DBS Labs for urinary serotonin and
dopamine neurotransmitter testing in
natural treatment of disease. DBS Labs
is directed by Tom Uncini, MD hospital
based pathologist who is dual board
certified in laboratory medicine. Dr.
Uncini is the medical director of two
hospital labs, University of Minnesota
Medical Center Mesabi in Hibbing, MN and
Cook Hospital in Cook, MN. Dr. Uncini is
also on the faculty of the University of
Minnesota Medical School. The urinary
neurotransmitter testing produced by DBS
Labs is of hospital caliber. Between Dr. Uncini and his lab manager there are over 50 years of hospital based laboratory experience.
The
experience and credentials of the people
running DBS Labs stand in stark contrast
to the other labs out there attempting
to do urinary neurotransmitter testing.
Other laboratories have no hospital
based board certified laboratory
medicine pathologist running the lab, no
license to practice medicine, no
hospital privilege affiliation, no
clinic, no patients, and have never
treated one patient in clinic. Yet some are holding
out that they have the expertise to tell
doctors how to treat their patients when
the urinary neurotransmitter testing
results are reported back to the doctor.
This may explain why the testing results
of these labs do not correlate when the same
sample is run on split sample testing by
DBS Labs and the non-MD lab. These
non-MD labs are the labs
that are recommending and inducing
licensed medical doctors to get "baseline
urinary neurotransmitter testing" prior to treatment even
though there is no correlation between
testing prior to and once taking amino
acid precursors. |
|
|
Pike Lake
Duluth photo by Amy Gunthert |
|
| |
|
 |
|
Contact us or find a caregiver using
this approach. |
| |
neurotransmitter testing-BASELINE TESTING |
|
Written by:
Marty L.
Hinz, MD |
|
President
Clinical
Research |
|
NeuroResearch
Clinics,
Inc. |
|
Cape Coral, Florida USA Research Office |
|
|
|
neurotransmitter testing-BASELINE TESTING |
| |
| |
|
Medical schools and medical doctors
directing medical labs know that
baseline urinary neurotransmitter testing prior to starting
neurotransmitter treatment is of no
value. Tom Uncini, MD dual board
certified hospital based laboratory
pathologist and his company DBS
Labs have been waiting several years for
the non-MD labs to catch up with current
science. All labs other than DBS advocate
getting a baseline test prior to
starting neurotransmitter treatment,
these are the biochemist labs with no
medical license to care for patients.
The of practice baseline
neurotransmitter testing does nothing to
help the patient get better it only
lines the bank
account with money of those that
recommend it. The "baseline
urinary neurotransmitter testing"
approach is suboptimal and in most cases
achieves no relief of symptoms.
Serotonin and dopamine baseline urinary
neurotransmitter testing of the caliber
found in hospitals has no correlation with
testing once the person is taking 5-HTP, tyrosine, levodopa, and cysteine. The only advocates
we have seen of serotonin and dopamine
baseline urinary neurotransmitter testing appear to be labs with no board
certified hospital based laboratory pathologist (MD) in
charge, where almost all baseline
urinary neurotransmitter testing results returned
show serotonin to be low or in the low
end of the reference range.
BASELINE TESTING-IF IT IS NOT DIAGNOSTIC WHY DO IT?
At every
AMA continuing medical education conference this year
are physicians who report
they have tried using the baseline
serotonin
and dopamine
urinary neurotransmitter testing prior to
treatment with their patients.
The results reported are very uniform - almost none of the patients
treated under the approach of getting baseline testing
prior to treated
showed improvement of symptoms.
Serotonin
and dopamine
baseline
urinary neurotransmitter testing prior to
treatment does not indicate what the
dosing level
of
5-HTP, levodopa, and tyrosine
should be, nor does it
they tell how well a person is going to respond to
treatment
with
5-HTP, levodopa, and tyrosine. Therefore, baseline
serotonin
and dopamine
neurotransmitter levels are not useful
when deciding how to best treat a person
with
5-HTP, levodopa, and tyrosine.
In close examination of DBS Labs data in of people with and without
neurotransmitter disease it is apparent that both groups virtually
all have the same urinary serotonin and
dopamine levels prior to starting treatment. |
|
|
|
|
|
The University of Minnesota
Medical School neurotransmitter testing paper.
FROM PEER REVIEWED
LITERATURE
The novel
observations observed in this study include the
absence of a consistent relationship between
ingested 5-HTP and urinary serotonin excretion and
the unexpected influence of Tyrosine to reduce
urinary dopamine excretion. The description of the
three phases demonstrating the relationship between
5-HTP and urinary serotonin excretion is also novel
and probably is a reflection of serotonin
reabsorption in the kidney. The consistent and
statistically discernable ability of Tyrosine to
dampen fluctuations in urinary dopamine excretion is
also noteworthy. These processes might be
reflective of similar processes occurring in other
organs.
Both
stimulatory and inhibitory effects of dietary 5
HydroxyTryptophan and Tyrosine on urinary excretion
of serotonin and dopamine in a large human
population
George J. Trachte,
Thomas Uncini and Marty Hinz, Department of
Physiology and Pharmacology, University of MN
Medical School |
| |
|
|
|
neurotransmitter testing-BASELINE TESTING |
|
TRUE STORY OF BASELINE neurotransmitter testing
One physician reported he had treated over 100
people with the baseline neurotransmitter testing approach and, “none got better”. The real
question is, “Why would you treat over 100 people before
deciding the approach did not work?”
BASELINE TESTING FROM THE
LITERATURE
Depression in I. Kohlstadt (ed.) Food and Nutrients in Disease Management (CRC Press, 2009)
VI: PERSON EVALUATION,
SEROTONIN AND DOPAMINE
urinary neurotransmitter testing in treatment.
Full text of the Johns
Hopkins writing on
urinary
neurotransmitters and
depression
"Serotonin
and dopamine baseline
urinary neurotransmitter testing" in treatment prior to 5-HTP, tyrosine,
and/or dopa therapy is of no
value. There is no
correlation between baseline
serotonin and dopamine
urinary neurotransmitter testing once the
person is
taking 5-HTP, tyrosine, and/or
dopa. It is not
necessary or even useful to
measure "Serotonin and
dopamine baseline urinary
neurotransmitter testing
prior to treatment."
Urinary monoamine
neurotransmitter molecules
(serotonin and dopamine) do
not cross the blood brain
barrier. Urinary
monoamines serotonin,
dopamine neurotransmitter
molecules are not serotonin,
dopamine neurotransmitter molecules
filtered by the glomerulous
of the kidneys and excreted
into the urine. They
are urinary serotonin,
dopamine neurotransmitter
molecules that are
synthesized by the kidneys
and excreted into the urine
or secreted into the system
via the renal veins.
With simultaneous
administration of serotonin
and dopamine precursors
5-HTP, tyrosine, and/or
levodopa, three phases of
serotonin and dopamine
urinary neurotransmitter testing response have
been identified on
laboratory assay of the
urine. The three
phases of response apply to
both serotonin and dopamine.
Serotonin and dopamine
urinary neurotransmitter testing results in all life forms that have
kidneys along with serotonin
and catecholamine systems,
the three phases of
serotonin, dopamine urinary
neurotransmitter response were
present in previous writings
but were not identified as
such. For example, a 1999
article notes that
administration of dopa can
increase urinary dopamine
levels (neurotransmitter
phase 3) and
decrease urinary serotonin
levels (neurotransmitter
phase 1).
neurotransmitter testing-BASELINE TESTING |
|
|
|
|
